Aktis Oncology | Biotech & Life Sciences | F4

Introducing F4 Champions, a new accelerator for founders at the earliest stage.F4 Champions for early-stage foundersEnrollment closesAugust 2Learn more

Team Portfolio Raise Champions Essays

F4/Aktis Oncology

Company Overview Backed By Recent Activity Similar Companies Startup DNA

Aktis Oncology

Aktis Oncology is committed to improving outcomes for cancer patients by pioneering a new class of targeted radiopharmaceuticals addressing prevalent tumor types that historically have been beyond the reach of radiopharmaceuticals

aktisoncology.com

Biotech & Life Sciences

Sector

Seed

Stage

Biotechnology

Model

01Company Overview

02Backed By2 investors

VVVida Ventures→MBMPM BioImpact→

Is this your company? Claim your profile

Startup Intelligence by F4F4 Research Engine

Recent Activity

FROM MPM BioImpact

Portfolio company Aktis Oncology priced an upsized IPO at $18/share, raising approximately $318M gross proceeds and began trading on Nasdaq as AKTS.

MILESTONE·globenewswire.com

JAN 9, 2026

FROM MPM BioImpact

Participated in Aktis Oncology's oversubscribed $175M Series B financing to advance its radiopharmaceutical pipeline.

INVESTMENT·prnewswire.com

SEP 30, 2024

04Similar Companies

FP

Fusion Pharmaceuticals

Biotech & Life Sciences

→

R

Rayzebio

Biotech & Life Sciences

→

AI

AdvanCell Isotopes

Biotech & Life Sciences

→

AP

Ablaze Pharma

Biotech & Life Sciences

→

A

Actithera

Biotech & Life Sciences

→

05Startup DNA

signals

Sectors
Business Model
Technology

Quick Reference

Sector

Biotech & Life Sciences

Website

aktisoncology.com

Visit aktisoncology.com ↗